Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 100 of 130 matching drugs for AKT2 — including drugs targeting any of its 45 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib AKT2 Direct 3
capivasertib AKT2 Direct 1
adagrasib KRAS SSL via KRAS yes 2
afatinib EGFR SSL via EGFR yes 2
dacomitinib EGFR SSL via EGFR yes 2
erlotinib EGFR SSL via EGFR yes 2
gefitinib EGFR SSL via EGFR yes 2
sotorasib KRAS SSL via KRAS yes 2
lazertinib and amivantamab EGFR SSL via EGFR 1
olaparib PARP1 SSL via PARP1 yes 1
osimertinib EGFR SSL via EGFR yes 1
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib AKT1 SSL via AKT1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib AKT3 SSL via AKT3 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib LCK SSL via LCK 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib MAP2K2 SSL via MAP2K2 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib PIK3CA SSL via PIK3CA 3
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel IGF1R SSL via IGF1R 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel MAP2K2 SSL via MAP2K2 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment LCK SSL via LCK 2
binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib MAP2K2 SSL via MAP2K2 2
cft1946, trametinib, cetuximab MAP2K2 SSL via MAP2K2 2
cixutumumab, everolimus, laboratory biomarker analysis, octreotide acetate, pharmacological study IGF1R SSL via IGF1R 2
cixutumumab, laboratory biomarker analysis, paclitaxel, pharmacological study IGF1R SSL via IGF1R 2
jab-3312, binimetinib, pembrolizumab, sotorasib, osimertinib MAP2K2 SSL via MAP2K2 2
nintedanib LCK SSL via LCK 2
nintedanib, pembrolizumab LCK SSL via LCK 2
selumetinib, medi4736, tremelimumab MAP2K2 SSL via MAP2K2 2
afatinib, dasatinib, palbociclib, everolimus, olaparib LCK SSL via LCK 1
akt inhibitor mk2206, fluorouracil, oxaliplatin, selumetinib MAP2K2 SSL via MAP2K2 1
alpelisib, everolimus, exemestane PIK3CA SSL via PIK3CA 1
aminolevulinic acid ALAD SSL via ALAD 1
aminolevulinic acid, surgical resection ALAD SSL via ALAD 1
arsenic trioxide AKT1 SSL via AKT1 1
arsenic trioxide, radiation therapy AKT1 SSL via AKT1 1
arsenic trioxide, temozolomide, adjuvant therapy, intensity-modulated radiation therapy, radiation therapy AKT1 SSL via AKT1 1
atorvastatin, temozolomide, radiotherapy HMGCR SSL via HMGCR 1
bevacizumab, dasatinib, placebo LCK SSL via LCK 1
binimetinib MAP2K2 SSL via MAP2K2 yes 1
binimetinib, hydroxychloroquine MAP2K2 SSL via MAP2K2 1
biopsy, biospecimen collection, ceralasertib, computed tomography, echocardiography, multigated acquisition scan, positron emission tomography, trastuzumab deruxtecan ATR SSL via ATR 1
biopsy, biospecimen collection, computed tomography, copanlisib, magnetic resonance imaging PIK3CA SSL via PIK3CA 1
biopsy, biospecimen collection, copanlisib, radiologic examination PIK3CA SSL via PIK3CA 1
bosutinib MAP2K2 SSL via MAP2K2 1
byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab LCK SSL via LCK 1
capivasertib AKT1 SSL via AKT1 1
capivasertib AKT3 SSL via AKT3 1
ceralasertib, olaparib, durvalumab ATR SSL via ATR 1
cisplatin, carboplatin, etoposide, durvalumab, ceralasertib ATR SSL via ATR 1
cytoreductive surgery, perifosine, temsirolimus AKT1 SSL via AKT1 1
dabrafenib, trametinib MAP2K2 SSL via MAP2K2 1
dabrafenib, trametinib, carboplatin, vincristine MAP2K2 SSL via MAP2K2 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride LCK SSL via LCK 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method LCK SSL via LCK 1
dasatinib, laboratory biomarker analysis, physiologic testing LCK SSL via LCK 1
dasatinib, mfolfox6 LCK SSL via LCK 1
dasatinib, pharmacological study LCK SSL via LCK 1
dasatinib, temozolomide, placebo, radiation therapy LCK SSL via LCK 1
enzastaurin, bevacizumab, enzyme-inducing antiepileptic drugs (eiaed), non-enzyme inducing antiepileptic drugs (neiaed) AKT1 SSL via AKT1 1
enzastaurin, lomustine AKT1 SSL via AKT1 1
enzastaurin, temozolomide, radiation therapy AKT1 SSL via AKT1 1
erlotinib hydrochloride, selumetinib, laboratory biomarker analysis MAP2K2 SSL via MAP2K2 1
gemcitabine, ribociclib, sonidegib, trametinib, filgrastim MAP2K2 SSL via MAP2K2 1
genistein, erlotinib hydrochloride, gemcitabine hydrochloride AKT1 SSL via AKT1 1
gsk2256098, trametinib MAP2K2 SSL via MAP2K2 1
insulin degludec, insulin glargine IGF1R SSL via IGF1R 1
irinotecan, cisplatin, simvastatin HMGCR SSL via HMGCR 1
laboratory biomarker analysis, linsitinib, pharmacological study, topotecan hydrochloride IGF1R SSL via IGF1R 1
laboratory biomarker analysis, perifosine, temsirolimus, therapeutic conventional surgery AKT1 SSL via AKT1 1
medical cannabis HMGCR SSL via HMGCR 1
nabiximols, temozolomide, nabiximols-matched placebo HMGCR SSL via HMGCR 1
perifosine AKT1 SSL via AKT1 1
ponatinib LCK SSL via LCK 1
rosuvastatin HMGCR SSL via HMGCR yes 1
selumetinib MAP2K2 SSL via MAP2K2 yes 1
semaglutide, insulin aspart, insulin glargine u100 IGF1R SSL via IGF1R 1
trametinib, erlotinib MAP2K2 SSL via MAP2K2 1
trametinib, ruxolitinib MAP2K2 SSL via MAP2K2 1
trametinib, ruxolitinib, retifanlimab MAP2K2 SSL via MAP2K2 1
trametinib, vinblastine MAP2K2 SSL via MAP2K2 1
afatinib dimaleate EGFR SSL via EGFR yes 0
alpelisib PIK3CA SSL via PIK3CA yes 0
atorvastatin HMGCR SSL via HMGCR yes 0
atorvastatin calcium HMGCR SSL via HMGCR yes 0
brigatinib IGF1R SSL via IGF1R yes 0
cerivastatin HMGCR SSL via HMGCR yes 0
cerivastatin sodium HMGCR SSL via HMGCR yes 0
cetuximab EGFR SSL via EGFR yes 0
cobimetinib MAP2K2 SSL via MAP2K2 yes 0
cobimetinib fumarate MAP2K2 SSL via MAP2K2 yes 0
copanlisib PIK3CA SSL via PIK3CA yes 0
copanlisib hydrochloride PIK3CA SSL via PIK3CA yes 0
dasatinib LCK SSL via LCK yes 0
erlotinib hydrochloride EGFR SSL via EGFR yes 0
fluvastatin HMGCR SSL via HMGCR yes 0
fluvastatin sodium HMGCR SSL via HMGCR yes 0
lapatinib EGFR SSL via EGFR yes 0
lapatinib ditosylate EGFR SSL via EGFR yes 0
lemborexant HCRTR1 SSL via HCRTR1 yes 0
lovastatin HMGCR SSL via HMGCR yes 0
mecasermin IGF1R SSL via IGF1R yes 0
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.